MICRORNA-21, MICRORNA-155 DAN MICRORNA-10B: BAGAIMANA PERANNYA PADA KANKER PAYUDARA?
Abstract
Abstrak. Kanker payudara merupakan jenis kanker yang masih banyak diderita perempuan, baik di negara maju maupun berkembang. Perubahan genetik pada gen regulator utama menyebabkan perubahan ekspresi protein sehingga memicu terjadinya kanker. Saat ini diketahui bahwa microRNA berperan sebagai regulator utama gen manusia dan juga terlibat dalam karsinogenesis kanker payudara. MicroRNA-21 (miR-21), microRNA-155 (miR-155) dan microRNA-10b (miR-10b) merupakan oncogenic miRNA yang memicu perkembangan kanker payudara melalui inhibisi protein tumorsuppressor. Tinjauan ini membahas mengenai peran, gen target tumorsuppresor dan dampaknya terhadap perkembangan, invasi dan metastasis kanker payudara. (JKS 2017; 2: 123-130)
Keyword: kanker payudara, miR-21, miR-155, miR-10b.
Abstract. Breast cancer is a type of cancer that still affects many women, and is found in both developed and developing countries. Genetic changes of the regulatory genes affect protein expression leading to cancer. It is known that microRNA has a role as a major regulator of human genes and involved in carcinogenesis of breast cancer. MicroRNA-21 (miR-21), microRNA-155 (miR-155) and microRNA-10b (miR-10b) are oncogenic miRNA that trigger the development of breast cancer through inhibition of tumorsuppressor protein. This review will discuss the role, target genes of tumorsuppressor and their impact on the development, invasion and metastasis of breast cancer. (JKS 2017; 2: 124-130)
Keyword: breast cancer, miR-21, miR-155, miR-10b
Keywords
References
Daftar Pustaka
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 2010; 127: 2893–2917.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013; 63:11-30.
Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia Tahun 2012. 2013. Diakses pada tanggal 10/03/2014. http://www.depkes.go.id/profil-kesehatan-indonesia/profil-kesehatan-indonesia-2012.pdf
Abdulkareem IH. A Review on aetio-pathogenesis of breast cancer. J Genet Syndr Gene Ther. 2013; 4: 1-4.
Kenemans P, Verstraeten RA, Verheijen RHM. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas. 2004; 49: 34–43.
Harada Y, Katagiri T, Ito I, Akiyama F, Sakamoto G, Kasumi F. Genetic studies of 457 breast cancers: Clinicopathologic parameters compared with genetic alterations. Cancer. 1994; 74(8): 2281–2286.
Nagahata T, Kosaka N, Shimizu M, Emi M. Molecular diagnosis for breast cancer. JMAJ. 2002; 45(6): 265–270.
Prasad GL. Tropomyosin-l, a putative tumor-suppressor and a biomarker of human breast cancer. U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland. 2004; DAMD 7-98-1-8162.
Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Research. 2008; 18: 350-359.
Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocrine-Related Cancer. 2003; 10: 193–202.
Lebrun JJ. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. International Scholarly Research Network ISRN Molecular Biology. 2012; 1-28.
Beckmann WM, Niederacher D, Schnürch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med. 1997; 75: 429- 439.
Ardekani AM, Naeini MM. The role of microRNAs in human diseases. Avicenna J Med Biotech. 2010; 2(4): 161-179.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–297
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001; 294: 853–858.
Hastings ML, Krainer AR. Pre-mRNA splicing in the new millennium. Curr Opin Cell Biol. 2001; 13(3): 302-309.
Bilen J, Nan L, Bonini NM. A new role for micro RNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle. 2006; 5(24): 2835-2838.
Pal M, Pal T. BRCA1 and miRNAs: An Emerging Therapeutic Target and Intervention Tool in Breast Cancer. Journal of PharmaSciTech. 2013; 3(1) : 9-19.
McManus DD, Ambros V. Circulating MicroRNA in Cardiovascular Disease. Circulation. 2011; 124(18): 1908-1910.
Fu SW, Chen L, Man YG. miRNA Biomarkers in Breast Cancer Detection and Management. Review. Journal of Cancer. 2011; 2: 116-122.
Calin GA, Croce CM. MicroRNA-Cancer Connection: The Beginning of a New Tale. Cancer Res. 2006; 66:7390-7394.
Cho WCS. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007; 6:60–66.
Ostad SN, Parsa M. Breast cancer from molecular point of view: pathogenesis and biomarkers, breast cancer - focusing tumor microenvironment, stem cells and metastasis. InTech. 2011
Croce CM, Calin GA. miRNAs, cancer, and stem cell division. J.Cell. 2005; 6(36):
-7.
Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259–269.
Lu M, Zhang Q, Deng M, Miao J, Guo Y. An Analysis of Human MicroRNA and Disease Associations. PLoS ONE. 2008; 3(10): 1-5.
Naeini MM, Ardekani AM. Noncoding RNAs and Cancer. Avicenna J Med Biotech. 2009; 1(2): 55-70.
Ikeda S, Pu WT. Expression and Function of MicroRNAs in Heart Disease. Current Drug Targets. 2010; 11: 1-13.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. PNAS. 2002; 99(24): 15524–15529.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65:7065–7070.
Christodoulatos GS, Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis?. World J Clin Oncol. 2014; 5(2): 71-81.
Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004; 10:1957–1966.
Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biology. 2011; 8(5): 706-713.
Jazbutyte V, Thum T. MicroRNA-21: From Cancer to Cardiovascular Disease. Current Drug Targets. 2010; 11: 926-935.
Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 Targets the tumor suppressor gene Tropomyosin 1 (TPM1). J Biol Chem. 2007; 282:14328-14336.
Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008; 283(2):1026–1033.
Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. PNAS. 1999; 96(24): 14037–14042.
Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation,in vitro migration and in vivo tumor growth. Breast Cancer Research. 2011; 13: 1-14.
Krichevsky AM, Gabriely G. MiR-21: a small multifaceted RNA. J. Cell. Mol. Med. 2009; 13(1): 39-53.
Yan LX, Huang XF, Shao Q, Huang MY, Deng L. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14: 2348-2360.
Qian B, Katsaros D, Lu L. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2009; 117:131–140.
Lee JA, Lee HY, Lee ES, Kim I, Bae JW. Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. J Breast Cancer. 2011; 14 (4): 269-275.
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007; 26:2799-2803.
Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. MiniReview. Cancer Epidemiology, Biomarkers and Prevention. 2012; 1236-1243.
Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. Journal of Biomedical Science. 2013; 20(79): 1-10.
Liu J, Huang W, Yang H, Luo Y. Expression and function of miR-155 in breast cancer. Biotechnology & Biotechnological Equipment. 2015; 29(5): 840-843
Biagoni F, Ben-Moshe NB, Fontemaggi G, Canu V, Mori F, Antoniani B. miR-10b, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med. 2012; 4: 1214–1229.
Ahmad A, Sethi S, Chen W, Ali-Fehmi R, Mittal S, Sarkar FH. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res. 2014; 6(4):384-390.
Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Molecular Cancer. 2014; 13:256
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research. 2010; 12:R90
Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Research. 2010; 12:210.
Takahashi Ryou-u, Miyazaki H, Ochiya T. The roles of microRNAs in breast cancer. Cancers. 2015; 7: 598-616.
Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB, Sarkar FH. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer. 2015; 15: 540.
Hafez MM, Hassan ZK, Zekri ARN, Gaber AA, Al Rejaie SS, Sayed-Ahme MM, et al. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pacific J Cancer Prev. 2013; 13:591-598.
DOI: 10.24815/jks.v17i2.8991
Refbacks
- There are currently no refbacks.